October 2022 Issue Table Of Contents

From The Editor

• Tiptoeing Toward A Cure For Type 1 Diabetes

Feature Articles

• Imagine Pharma’s Multilayered Path To Market

Companies To Watch

• CytoAgents

Industry Research

• Outsourced Proportion Of Phase 2/3 Spend

Podcast Summary

• What’s True Of Mice ≠ What’s True Of Men

Inside The Industry

• Where Bioprocessing Outsourcers Stand On Capacity Concerns
• The Unsexy But Essential Side Of AI In Life Sciences
• How To Navigate Drug Repurposing And Bridging Studies
• Inside The Culture Transformation Initiative At GSK Vaccines
• The Discovering CEO
• 6 Reasons Why India Is The Future Of Global Production Of Apis
• Data: The Future Of Regulatory Info Management In Europe
• What Has Changed With The R&D Tax Credit?
• What Is A Risk-Based Approach To CRO Oversight?
• WOCIP Conference To Focus On “The Power Of We”

Industry Leader

• Open Innovation Is The Path To True Innovation
• Why Life Science Firms Need Tech Specialists On Boards

Leadership Lessons

• Leading With The HAT Principle

Ask The Board

• Your New Book Is Pharma And Profits: Balancing Innovation, Medicine And Drug Pricing. What Is Most Often Overlooked In Political Discussions About Drug Prices?
• How Can Novel Data Registries Inform The Development Of New Medicines, Or Improve Patient Care?
• How Can Company Leaders Maintain Commercial Momentum With Marketed Products Without Losing Focus On New Drug Development Programs?